phrykt

Spruce Biosciences, Inc. (SPRB): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of SPRB were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Spruce Biosciences

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SPRB

64 funds and institutions reported SPRB shares worth $108M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is AIGH Capital Management LLC with 18.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

AIGH Capital Management LLC18.2%
Orbimed Advisors LLC14.6%
BlackRock, Inc.13.7%
Millennium Management LLC11.7%
Ikarian Capital, LLC8.8%
Vanguard Capital Management LLC8.7%
Alyeska Investment Group, L.P.6.0%
Geode Capital Management, LLC5.1%
ADAR1 Capital Management, LLC4.9%
Cable Car Capital, LP4.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
AIGH Capital Management LLC250,00018.22%$13.5MNew
Orbimed Advisors LLC200,00014.58%$10.8MNew
BlackRock, Inc.187,83613.69%$10.1M+1009%
Millennium Management LLC160,98111.73%$8.7M+44%
Ikarian Capital, LLC121,3568.84%$6.6MNo change
Vanguard Capital Management LLC119,3318.70%$6.4M+551%
Alyeska Investment Group, L.P.81,6715.95%$4.4M+58%
Geode Capital Management, LLC70,5485.14%$3.8M+447%
ADAR1 Capital Management, LLC67,7174.94%$3.7M+16%
Cable Car Capital, LP60,0004.37%$3.2MNew
Citadel Advisors LLC51,9053.78%$2.8M-26%
State Street Corp50,4503.68%$2.7M+834%
Boothbay Fund Management, LLC42,0803.07%$2.3MNo change
Stempoint Capital LP41,3883.02%$2.2M+225%
Eversept Partners, LP40,0002.92%$2.2MNew
Carlyle Group Inc.38,6202.81%$2.1MNo change
Goldman Sachs Group Inc32,3482.36%$1.7M+488%
Diadema Partners LP30,0002.19%$1.6M+200%
Affinity Asset Advisors, LLC30,0002.19%$1.6MNew
Stonepine Capital Management, LLC28,7952.10%$1.6MNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No SPRB insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SPRB short interest

High short interest. 18.5% of SPRB shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 147%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 531,380 SPRB shares were sold short, 18.5% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 76,446 shares, buying them all back would take about 7.0 trading days (days to cover).

Shares short, % of all shares

18.5%May 15Oct 3033.9%

Days to cover

7.0May 15Oct 3011.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026531,38018.49%+2%76,4467.0
Oct 15, 2026522,12018.17%+21%78,8476.6
Sep 30, 2026431,54115.02%+4%95,3334.5
Sep 15, 2026416,14014.48%-5%125,0923.3
Aug 31, 2026440,24315.32%+9%73,6856.0
Aug 14, 2026403,03114.02%-6%38,68110.4
Jul 31, 2026429,12231.28%+3%56,4477.6
Jul 15, 2026415,86030.31%+16%68,2636.1
Jun 30, 2026359,38926.19%+37%114,0153.1
Jun 15, 2026262,61619.14%+9%50,0605.2
May 29, 2026241,92717.63%+12%57,2624.2
May 15, 2026215,06115.67%+4%36,7665.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Spruce Biosciences company events

Spruce Biosciences filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 12, 2026ResultsReleased financial results. Filing
  3. Jul 27, 2026LeadershipSpruce Biosciences, Inc. appointed Adrian Quartel, M.D., FFPM, as the Company’s Chief Medical Officer, replacing Dr. Kirk Ways, who had been serving as the Company’s Interim Chief Medical Officer. Filing
  4. May 26, 2026VoteReported shareholder vote results. Filing
  5. May 13, 2026ResultsReleased financial results. Filing
  6. Apr 22, 2026AgreementSpruce Biosciences, Inc. entered into an underwriting agreement with Leerink Partners LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc., as representatives of the several underwriters listed therein, to issue and sell 1,150,000 shares of the Company’s common stock, par value $0.0001 per… Filing
  7. Mar 20, 2026AgreementEnded an important agreement. Filing
  8. Mar 9, 2026LeadershipThe Company announced the appointment of Corwin Dale Hooks as the Company’s Chief Commercial Officer, effective March 9, 2026. Filing
  9. Feb 5, 2026AnnouncementThe Presentation included final results from the Company’s new analyses of its existing data from Observational Study 902 and Interventional Studies 250-201, 250-202, and 250-401 for the treatment of MPS IIIB using the validated Vineland Adaptive Behavior Scales, Second Edition scale. Filing
  10. Jan 8, 2026AgreementSpruce Biosciences, Inc. entered into a Loan and Security Agreement and a Supplement to the Loan and Security Agreement (together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Capital Management II, L.P., as administrative agent and collateral agent and Avenue Venture… Filing
  11. Dec 15, 2025LeadershipThe board of directors of Spruce Biosciences, Inc. appointed Keli Walbert to the Board, effective immediately. Filing
  12. Dec 12, 2025LeadershipTiba Aynechi, Ph.D. notified Spruce Biosciences, Inc. of her resignation as a member of the board of directors of the Company and as the Chair of the Compensation Committee of the Board, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Spruce Biosciences financials

Famous investors that hold SPRB

3 of the 50 well-known investors we track reported holding SPRB in their latest 13F filing. The largest position is Israel Englander's, worth $6.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026136,675$6.6M0.0%-15%
Ken Griffin · Citadel AdvisorsQ3 202690,610$4.4M0.0%+75%
Steve Cohen · Point72 Asset ManagementQ3 202644,258$2.2M0.0%+57%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SPRB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026OrbiMed Advisors LLC13G/A5.6%
Nov 16, 2026OrbiMed Advisors LLC13G/A5.6%

Questions about Spruce Biosciences, Inc. (SPRB) stock

Who owns the most SPRB stock?

The largest reported owner of Spruce Biosciences, Inc. (SPRB) is AIGH Capital Management LLC, with 18.2% of the company. In total, 64 funds and institutions reported holding SPRB at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SPRB insiders buying or selling?

No SPRB insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in SPRB?

As of Oct 30, 2026, 531,380 SPRB shares were sold short, 18.5% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 76,446 shares, buying them all back would take about 7.0 trading days (days to cover). See the history.

Which famous investors hold SPRB?

3 of the 50 well-known investors we track reported SPRB in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $6.6M. See all holders.

Executive pay

Spruce Biosciences's chief executive was paid a total of $2.9M for the year ended Dec 31, 2025, up 90% from $1.5M the year before. In the last 12 months, Spruce Biosciences's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$2.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.